The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Recombinant vaccines for COVID-19
Open accessAbstract
SARS-CoV-2, the causative agent of COVID-19, has imposed a major public health threat, which needs effective therapeutics and vaccination strategies. Several potential candidate vaccines being rapidly developed are in clinical evaluation. Considering the crucial role of SARS-CoV-2 spike (S) glycoprotein in virus attachment, entry, and induction of neutralizing antibodies, S protein is being widely used as a target for vaccine development. Based on advances in techniques for vaccine design, inactivated, live-vectored, nucleic acid, and recombinant COVID-19 vaccines are being developed and tested for their efficacy. Phase3 clinical trials are underway or will soon begin for several of these vaccines. Assuming that clinical efficacy is shown for one or more vaccines, safety is a major aspect to be considered before deploying such vaccines to the public. The current review focuses on the recent advances in recombinant COVID-19 vaccine research and development and associated issues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have found that the S protein prefusion conformation induces better immunogenicity and can be therefore considered an ideal target antigen.237”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [237]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., Neuman, B. W., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0695-z · Cited by 8,745
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
Rothan, H. A., & Byrareddy, S. N. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102433 · Cited by 5,840
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y. Z., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,069
Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins
Lam, T. T., Jia, N., Zhang, Y.-W., Shum, M. H.-H., Jiang, J.-F., Zhu, H., Tong, Y., Shi, Y., Ni, X.-B., Liao, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2169-0 · Cited by 1,877
Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., & Du, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0400-4 · Cited by 1,654
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
(2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0772 · Cited by 1,537
Development of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434
Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382
Liu, C., Zhou, Q. A., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S. R., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,317
The Novel Coronavirus Originating in Wuhan, China
Phelan, A., Katz, R., & Gostin, L. O. (2020) · JAMA · doi:10.1001/jama.2020.1097 · Cited by 1,210
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997
Cross‐species transmission of the newly identified coronavirus 2019‐nCoV
Ji, W., Wang, W., Zhao, X., Zai, J., & Li, X. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25682 · Cited by 942
Song, W., Gui, M., Wang, X., & Xiang, Y. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007236 · Cited by 842
Xu, J., Zhao, S., Teng, T., Abdalla, A. E., Zhu, W., Xie, L., Wang, Y., & Guo, X. (2020) · Viruses · doi:10.3390/v12020244 · Cited by 693
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
Yang, Z.-Y., Kong, W., Huang, Y., Roberts, A., Murphy, B., Subbarao, K., & Nabel, G. (2004) · Nature · doi:10.1038/nature02463 · Cited by 688
Dhama, K., Sharun, K., Tiwari, R., Dadar, M., Malik, Y. S., Singh, K. P., & Chaicumpa, W. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1735227 · Cited by 622
Self-citationKushnir, N., Streatfield, S. J., & Yusibov, V. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 610
Immunogenicity of a DNA vaccine candidate for COVID-19
Smith, T. R. F., Patel, A., Ramos, S., Elwood, D., Zhu, X., Yan, J., Gary, E. N., Walker, S. N., Schultheis, K., Purwar, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16505-0 · Cited by 601
Major findings and recent advances in virus–like particle (VLP)-based vaccines
Mohsen, M. O., Zha, L., Cabral‐Miranda, G., & Bachmann, M. F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.014 · Cited by 560
Developments in Viral Vector-Based Vaccines
Ura, T., Okuda, K., & Shimada, M. (2014) · Vaccines · doi:10.3390/vaccines2030624 · Cited by 457
Is COVID-19 receiving ADE from other coronaviruses?
Tetro, J. A. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.02.006 · Cited by 439
Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS
Drexler, J. F., Corman, V. M., & Drosten, C. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.10.013 · Cited by 415
Kim, E., Erdös, G., Huang, S., Kenniston, T. W., Balmert, S. C., Carey, C. D., Raj, V. S., Epperly, M. W., Klimstra, W. B., Haagmans, B. L., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102743 · Cited by 405
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic
Lythgoe, M. P., & Middleton, P. K. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.03.006 · Cited by 379
Weingartl, H. M., Czub, M., Czub, S., Neufeld, J., Marszal, P., Gren, J., Smith, G. A., Jones, S. E., Proulx, R., Deschambault, Y., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12672-12676.2004 · Cited by 344
The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
Shang, W., Yang, Y., Rao, Y., & Rao, X. (2020) · npj Vaccines · doi:10.1038/s41541-020-0170-0 · Cited by 275
Kumar, S., Maurya, V. K., Prasad, A. K., Bhatt, M. L. B., & Saxena, S. K. (2020) · VirusDisease · doi:10.1007/s13337-020-00571-5 · Cited by 228
Self-citationAbdelmageed, M. I., Abdelmoneim, A. H., Mustafa, M. I., Elfadol, N. M., Murshed, N. S., Shantier, S. W., & Makhawi, A. M. (2020) · BioMed Research International · doi:10.1155/2020/2683286 · Cited by 205
Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees
Jiang, S. (2020) · Nature · doi:10.1038/d41586-020-00751-9 · Cited by 174 · cited 1×
“Therefore, the corresponding regulatory authorities should evaluate the safety profile of potential SARS-CoV -2 vaccines using an array of virus strains and a variety of animal models.(48)”
BackgroundSpruth, M., Kistner, O., Savidis-Dacho, H., Hitter, E., Crowe, B. A., Gerenčer, M., Brühl, P., Grillberger, L., Reiter, M., Tauer, C., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.055 · Cited by 121
What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?
Rosales‐Mendoza, S., Márquez-Escobar, V. A., González‐Ortega, O., Nieto‐Gómez, R., & Arévalo-Villalobos, J. I. (2020) · Vaccines · doi:10.3390/vaccines8020183 · Cited by 103
Zhou, J., Wang, W., Zhong, Q., Hou, W., Yang, Z., Xiao, S., Runqing, Z., Tang, Z., Wang, Y., Xian, Q., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.11.075 · Cited by 78
Global Trends in Epidemiology of Coronavirus Disease 2019 (COVID-19)
Srivastava, N., Baxi, P., Ratho, R. K., & Saxena, S. K. (2020) · Medical virology · doi:10.1007/978-981-15-4814-7_2 · Cited by 60
Self-citationPrevention and Control Strategies for SARS-CoV-2 Infection
Srivastava, N., & Saxena, S. K. (2020) · Medical virology · doi:10.1007/978-981-15-4814-7_11 · Cited by 33
Self-citationWang, J., & Zand, M. S. (2020) · Journal of Clinical and Translational Science · doi:10.1017/cts.2020.39 · Cited by 26
Research works printed but not linked: 7
- 10.1016/j.cell.2020.02.058 · DOI · Paper page
- Prompetchara E, 2020, Asian Pac J Allergy Immunol, 38, 1
- Pharmaceutical Business Review. 2020 Apr 18. [Accessed 2020 Aug 31]. https://www.pharmaceutical-business-review.com/news/sinovac-biotech-covid-19-vaccine-trial/.
- Oncosec. 2020 Apr 18. [Accessed 2020 Aug 31]. https://ir.oncosec.com/press-releases/detail/2042/oncosec-collaborates-with-providence-cancer-institute-to.
- Tazehkand MN, 2020, J Vaccines Vaccin, 11, 411
- Glaxo. GlaxoSmithKline press release on 2/24/20; 2020 Apr 11. [Accessed 2020 Aug 31]. https://www.gsk.com/en-gb/media/press-releases/clover-and-gsk-announce-researchcollaboration-to-evaluate-coronavirus-covid-19-vaccine-candidatewith-pandemic-adjuvant-system.
- Generex. press release on 2/27/2020; 2020. [Accessed 2020 Aug 31]. https://storage.googleapis.com/wzukusers/user26831283/documents/5e57ed391b286sVf68Kq/PR_Generex_Coronavirus_Update_2_27_2020.pdf.
Cited by
Sorted by citations
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Supasa, P., Zhou, D., Dejnirattisai, W., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Nutalai, R., Tuekprakhon, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.033 · Cited by 460
Choudhary, S., Malik, Y. S., & Tomar, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01664 · Cited by 231
Maleki, A., Look-Why, S., Manhapra, A., & Foster, C. S. (2021) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v16i3.9443 · Cited by 92
Tracking the COVID-19 vaccines: The global landscape
Yadav, T., Kumar, S., Mishra, G., & Saxena, S. K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2191577 · Cited by 82
Self-citation
Metadata
- Authors
- Yadav, T., Srivastava, N., Mishra, G., Dhama, K., Kumar, S., Puri, B., & Saxena, S. K.
- Affiliations
- Department of Zoology, Jawaharlal Nehru Smriti Government Post Graduate College, Shujalpur, India
- Department of Biotechnology, Meerut Institute of Engineering and Technology, Meerut, India
- Indian Veterinary Research Institute (IN)
- King George's Medical University (IN)
- Corresponding author
- Saxena, Shailendra K
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2020-11-24
- Volume
- 16
- Issue
- 12
- Pages
- 2905-2912
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- PMC
- PMC7711739
- OpenAlex
- W3110025561
- Cited by
- 105
- References
- 41
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 14 · 2023: 20 · 2022: 40 · 2021: 22 · 2020: 2
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Vaccines & Immunotherapeutics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- CCRH
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- COVID-19 vaccines, SARS-CoV-2, recombinant vaccine, spike protein, vaccine design, vaccine safety, vaccine efficacy, nucleic acid vaccines, inactivated vaccine
- MeSH terms
- COVID-19, COVID-19 Vaccines, Genetic Vectors, Humans, Vaccines, Synthetic, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
